Antisoma, Novartis launch ASA404 trial in Japan

Researchers for Antisoma and Novartis have begun enrolling patients in Japan for a late-stage trial of ASA404 as a first-line treatment for non-small cell lung cancer--a big step toward seeking an approval in the key Asian market. Novartis inked an $890 million licensing pact with Antisoma in 2007. Release | Report